Biomarkers, if used appropriately, could ensure patients receive the appropriate treatment sooner, and that they have better outcomes at reduced costs. But despite the potential and expanding capabilities, barriers to full-fledged use remain.
Approvals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar.
In 2014, nearly 2 million Americans met the diagnostic criteria for a past-year prescription opioid use disorder, and at least 14,000 people died from a prescription opioid overdose. Read about the top drivers and risk factors.